Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9668 in Cystic Fibrosis
NCT00757848Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing AZD9668 with Placebo (2 arms). Primary endpoints: Ratio of Sputum Absolute Neutrophil Count at End of Treatment Compared to Baseline at Day 28, Sputum Percentage Neutrophil Count at Day 28 and 8 more. Started Oct 2008; status: completed.
02
Drugs
alvelestat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00757848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757848.